Le Lézard
Classified in: Health, Science and technology
Subjects: HEALTH, Philanthropy

Brain Canada Launches $26 Million Platform Support Grants (PSG) Program to Accelerate Neuroscience and Mental Health Research



MONTREAL, June 20, 2024 (GLOBE NEWSWIRE) -- Brain Canada is thrilled to announce the launch of the 2024 Platform Support Grants (PSG) program, a groundbreaking initiative designed to bridge a critical gap in the neuroscience research funding environment. By fostering innovation and interdisciplinary collaboration through enhanced research platforms, this unique program aims to significantly advance the field of neuroscience and mental health research.

Recognizing the essential role that research platforms play in addressing the evolving needs of high-impact research, Brain Canada has committed $13 million in new federal funding through the Canada Brain Research Fund. This amount will be matched by funding from sponsors secured by applicants, creating a total funding envelope of $26 million.

"Today's brain research requires access to sophisticated shared resources like equipment, facilities, databases, and biobanks, collectively known as platforms," said Dr. Viviane Poupon, President and CEO of Brain Canada. "With the Government of Canada's recent $80 million investment in brain research, we are pleased to launch the 2024 PSG program, which will enable researchers to address the evolving needs of neuroscience and mental health research."

Platform Support Grants Program Overview

The PSG program supports major research platforms at a local, regional, or national scale with the goal of providing enhanced technical and research capabilities to multiple investigators in the neurosciences. Researchers can apply for funding through two streams:

Stream 1: Will support platforms that are in development or already existing but that have never been funded through Brain Canada's Platform Support Grants program.

Stream 2: Will support platforms that have previously received funding through Brain Canada's Platform Support Grants program.

Historically, research grants awarded through the PSG program have ranged from $138,000 - $6.1 million (including matching funds) across the grant duration.

The deadline for applicants to submit their registration forms is July 24, 2024, and the full application deadline is September 20, 2024.

For full application details, please visit Brain Canada's website.

This program is made possible by the Canada Brain Research Fund (CBRF), an innovative arrangement between the Government of Canada (through Health Canada) and Brain Canada.

About Brain Canada

Brain Canada plays a unique and invaluable role as a national convenor of those who support and advance brain research. A greater understanding of how the brain works contributes to the prevention, diagnosis, treatment and cure of disorders of the brain, ultimately improving the health outcomes of people in Canada and around the world. To learn more, visit Braincanada.ca @BrainCanada

Media Contact

Brielle Goulart

Communications & Marketing Officer

[email protected]

450-915-2253

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5dab73e4-5b31-41e1-b061-d05ab61f8d20



These press releases may also interest you

at 02:03
Barrington James, a global leader in Life Science Recruitment, proudly announces the acquisition of S3 Science Recruitment, a firm renowned for its expertise in drug discovery, medical research, and the broader field of life sciences. Terms of the...

at 02:00
July 3, 2024 Amsterdam, the Netherlands ? Royal Philips , a global leader in health technology, today announced the appointment of Ms Ling Liu as the Chief Region Leader of Philips Greater China, effective immediately. Ms Liu is now a member of...

at 01:39
Hansa Biopharma, "Hansa" , will publish its interim report for January-June 2024 on July 18, 2024. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST/8:00 AM EST. The event will be hosted by Søren...

at 01:05
Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today announces a change to its Executive Leadership Team...

at 00:15
In the news release, AbbVie, Inc.'s Zymaxid tm Implicated in Product Liability Lawsuit Due to Risk of Serious Injury and Death, issued 02-Jul-2024 by Wormington & Bollinger over PRWeb, the source of the release should be "Wormington & Bollinger"...

at 00:00
Author David W. Treaster shares a Christian-based plan that can supplement a cancer patient's medical treatment plan in God Power Cancer Healing Plan: Spiritual Component ($15.99, paperback, 9781662899942; $7.99, e-book, 9781662899959). As long as...



News published on and distributed by: